Ancient herbal remedy tested for early menopause relief
NCT ID NCT07020429
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether adding a traditional Chinese herbal formula called Huanjingjian decoction to standard hormone therapy can improve symptoms and quality of life in women with premature ovarian insufficiency (early menopause). About 276 women aged 18-39 will receive either the herbal formula plus hormone therapy or a placebo plus hormone therapy for three months. Researchers will track symptom changes, hormone levels, and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Huanjingjian decoction (a traditional Chinese herbal formula)
- What this could lead to
- If it works, this could offer an additional treatment option to help manage symptoms and improve quality of life for women with premature ovarian insufficiency.
- What could go wrong
- This is an early-stage trial with no phase designation, so results are uncertain. The herbal formula may not provide added benefit beyond standard hormone therapy, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 276 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Jul 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 39 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 39 years * Meet the diagnostic criteria for Premature Ovarian Insufficiency (POI) according to the 2024 ESHRE Guideline on Premature Ovarian Insufficiency Exclusion Criteria: * Menstrual disorders attributable to congenital gonadal dysgenesis or acquired structural pathologies; * Menstrual irregularities secondary to endocrine disorders, including polycystic ovary syndrome (PCOS), hyperprolactinemia, dysfunctional uterine bleeding (DUB), gonadal hormone deficiency, hyperthyroidism, and other related endocrine conditions; * Oligomenorrhea or amenorrhea induced by surgical or medical interventions, such as chemotherapy, pelvic radiotherapy, ovarian cystectomy, ovarian drilling, ovarian wedge resection, salpingectomy, tubal ligation, pelvic abscess surgery, or uterine artery embolization; * History of abnormal vaginal bleeding accompanied by clinically significant findings on endometrial biopsy, or unexplained irregular vaginal bleeding within the preceding 12 months; * Suspected cervical malignancy or precancerous cervical lesions, suspected malignant breast tumors, or a known or suspected history of hormone-dependent tumors or malignancies; * Previous or current history of deep vein thrombosis (DVT), pulmonary embolism, thrombotic disorders, or cerebrovascular events (stroke); * Presence of uncontrolled and/or undiagnosed systemic diseases that could confound study results or compromise patient safety, including severe hepatic, renal, cardiac, or neurological disorders; * Known hypersensitivity or allergy to any study-related medications; * Pregnancy or lactation; * Participation in other clinical trials within the last 3 months; * Failure or refusal to provide written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Premature ovarian insufficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Jingan hospital of Traditional Chinese Medicine
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Own bone marrow cells aimed at restarting ovaries
- Kidney drug tested to restart egg growth in early menopause
- Can umbilical cord stem cells revive failing ovaries?
- Major study launches to unravel mysteries of early menopause
- DNA hunt for why some women face early menopause
- Stem cell shot into ovaries aims to tame perimenopause symptoms